Prognostic value of noninvasive testing one year after orthotopic cardiac transplantation
PP Verhoeven,
FA Lee,
TM Ramahi,
KL Franco,
C Mendes de Leon,
J Amatruda,
NA Gorham,
JA Mattera,
and
FJ Wackers
Department of Internal Medicine (Section of Cardiovascular Medicine), Yale University School of Medicine, New Haven, Connecticut 06520-8042, USA.
OBJECTIVES: We sought to evaluate the prognostic value of routine noninvasive testing--stress thallium-201 imaging, rest two-dimensional echocardiography and rest equilibrium radionuclide angiography--1 year after cardiac transplantation. BACKGROUND: Coronary artery vasculopathy is the most important cause of late death after orthotopic cardiac transplantation. Several clinical variables have been identified as risk factors for development of coronary vasculopathy. Traditional noninvasive diagnostic testing has been shown to be relatively insensitive for identifying patients with angiographic vasculopathy. METHODS: Results of prospectively acquired noninvasive testing in 47 consecutive transplant recipients alive 1 year after transplantation were related to subsequent survival. Other clinical variables previously shown to be associated with the development of coronary artery vasculopathy were also included in the analysis. RESULTS: The 5-year survival rate after cardiac transplantation was 81%. By univariate analysis, echocardiography (chi-square 9.21) and stress thallium-201 myocardial perfusion imaging (chi-square 16.76) were predictive for survival, whereas rest equilibrium radionuclide angiography was not. Clinical contributors to survival were donor age (chi-square 4.56), number of human leukocyte antigen mismatches (chi-square 3.06) and cold ischemic time (chi-square 3.23). By multivariate analysis, stress myocardial imaging remained the only significant predictor of survival (risk ratio 0.27; 95% confidence interval 0.06 to 0.89). CONCLUSIONS: Normal thallium-201 stress myocardial perfusion imaging 1 year after cardiac transplantation is an important predictor of 5-year survival.
This article has been cited by other articles:
|
|
|
|
 
M. Hacker, H. X. Hoyer, C. Uebleis, P. Ueberfuhr, S. Foerster, C. La Fougere, and H.-U. Stempfle
Quantitative assessment of cardiac allograft vasculopathy by real-time myocardial contrast echocardiography: a comparison with conventional echocardiographic analyses and [Tc99m]-sestamibi SPECT
Eur J Echocardiogr,
July 1, 2008;
9(4):
494 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Myers, O. Geiran, S. Simonsen, A. Ghuyoumi, and L. Gullestad
Clinical and Exercise Test Determinants of Survival After Cardiac Transplantation
Chest,
November 1, 2003;
124(5):
2000 - 2005.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.R Ciliberto, L Ruffini, M Mangiavacchi, M Parolini, R Sara, D Massa, R De Maria, E Gronda, E Vitali, and O Parodi
Resting echocardiography and quantitative dipyridamole technetium-99m sestamibi tomography in the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis after heart transplantation
Eur. Heart J.,
June 1, 2001;
22(11):
964 - 971.
[Abstract]
[PDF]
|
|
|
|
